Furthermore, SMN levels are selectively increased by the administration of VPA modifying SMN1/2 promoter structure [12, 14]; VPA has already been tested on SMA and ALS patients [30–32], albeit mainly with negative results. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.